Company intelligence / Profile preview

Hager Biosciences

Bethlehem, Pennsylvania, United Stateshagerbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hager Biosciences operates as a preclinical-stage drug discovery company leveraging proprietary fragment-based chemistry platforms to generate and optimize small molecule leads for outlicensing to pharmaceutical and biotech partners. The company’s leadership has extensive experience in advancing compounds through the preclinical pipeline across multiple therapeutic areas. No clinical results or late-stage assets are publicly disclosed.

Therapeutic areas: OncologyImmunologyRheumatologyCardiovascularNeurologyWomen's Health
Modalities: Small moleculeFragment-based drug discovery (modular fragments)
Industry: Drug Discovery Services

Partnerships

Not publicly disclosed; business model centers on outlicensing leads to pharma/biotech partners but no named partnerships available.

Beyond the preview

Go deeper on Hager Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hager Biosciences.

Explore the full profile